Citigroup Maintains Buy on Apogee Therapeutics, Raises Price Target to $125

Citigroup analyst Geoff Meacham has maintained a Buy rating on Apogee Therapeutics (NASDAQ: APGE) and raised the price target from $95 to $125. This adjustment reflects a positive outlook for the company's performance in the market.